Application of 2,3-aziridino-γ-lactone methodology toward the enantiospecific synthesis of the (3S,4S)-isomer of dihydroxy-L-glutamic acid

Tetrahedron

Volumn 55, Issue 24, 1999, Pages 7589-7600

  Dauban, Philippe ^a   De Saint Fuscien, Carole ^a   Dodd, Robert H ^a  

^a CNRS   (France)

Author keywords

Azides; Aziridines; Glutamic acid; Lactones

Indexed keywords

AZIRIDINE DERIVATIVE; BENZYL ALCOHOL; BORON DERIVATIVE; FLUORIDE; GAMMA BUTYROLACTONE; GAMMA LACTONE DERIVATIVE; GLUTAMIC ACID DERIVATIVE; RIBOSE;

AMINO ACID SYNTHESIS; ARTICLE; CHEMICAL REACTION; CYCLIZATION; ENANTIOMER; HYDROGENATION; HYDROLYSIS; ISOMER; PRIORITY JOURNAL; STEREOSPECIFICITY;

EID: 0033546425     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00405-6     Document Type: Article

References (49)

1. For recent reviews, see : (a) Krogsgaard-Larsen, P.; Ebert, B.; Lund, T.M.; Bräuner-Osborne, H. ; Slok, F.A.; Johansen, T.N.; Brehm, L.; Madsen, U. Eur. J. Med. Chem. 1996, 31, 515.
2. (b) Knöpfel, T.; Kuhn, R.; Allgeier, H. J. Med. Chem. 1995, 38, 1417.
3. Nakanishi, S. Science 1992, 258, 597.
4. Conn, P.; Pin, J.-P. Ann. Rev. Pharmacol. Toxicol. 1997, 37, 205.
5. (e) Madge, D.J.; Batchelor, A.M. Ann. Rep. Med. Chem., Academic Press, 1996, Chapter 4.
6. (a) Monaghan, D.T.; Bridges, R.J.; Cotman, C.W. Ann. Rev. Pharmacol. Toxicol. 1989, 29, 365.
7. (b) Bliss, T.V.P.; Collingridge, G.A. Nature 1993, 361, 31.
8. Nakanishi, S. Neuron 1994, 13, 1031.
9. (a) Watkins, J.C. In The NMDA Receptor ; Watkins, J.C.; Collingridge, G.L., Eds.; IRL Press at Oxford University Press : Oxford, 1989.
10. (b) Olney, J.W. Ann. Rev. Pharmacol. Toxicol. 1990, 30, 47.
11. Meldrum, B. Brain Res. Rev. 1993, 18, 293.
12. Li, J.-H.; Bigge, C.F.; Williamson, R.M.; Borosky, S.A.; Vartanian, M.G.; Ortwine, D.F. J. Med. Chem. 1995, 38, 1955 and references therein.
13. For examples, see : (a) Yanagida, M.; Hashimoto, K.; Ishida, M.; Shinozaki, H.; Shirahama, H. Tetrahedron Lett. 1989, 30, 3799.
14. (b) Gu, Z.Q.; Hesson, D.P.; Pelletier, J.C.; Maccechini, M.L.; Zhou, L.M.; Skolnick, P. J. Med. Chem.. 1995, 38, 2518.
15. Ezquerra, J.; Pedregal, C.; Mico, I.; Najera, C. Tetrahedron:Asymmetry 1994, 5, 921.
16. Moody, CM.; Young, D.W. Tetrahedron Lett. 1994, 35, 7277.
17. (e) Del Bosco, M.; Johnstone, A.N.C.; Bazza, G.; Lopatriello, S.; North, M. Tetrahedron 1995, 51, 8545.
18. (f) Ouerfelli, O.; Ishida, M.; Shinozaki, H.; Nakanishi, K.; Ohfune, Y. Synlett 1993, 409.
19. (g) Wermuth, C.G.; Mann, A.; Schoenfelder, A.; Wright, R.A.; Johnson, B.G.; Burnett, J.P.; Mayne, N.G.; Schoepp, D.D. J. Med. Chem. 1996, 39, 814.
20. (a) Shimamoto, K.; Ishida, M.; Shinozaki, H.; Ohfune, Y. J. Org. Chem. 1991, 56, 4167.
21. (b) Raghavan, S.; Ishida, M.; Shinozaki, H.; Nakanishi, K.; Ohfune, Y. Tetrahedron Lett. 1993, 34, 5765.
22. Palmer, E.; Monaghan, D.T.; Cotman, C.W. Eur. J. Pharmacol. 1989, 166, 585.
23. (a) Garner, P. Tetrahedron Lett. 1984, 25, 5855.
24. (b) Roemmele, R.C.; Rapoport, H. J. Org. Chem. 1989, 54, 1866.
25. Dell'uomo, N.; Di Giovanni, M.C.; Misiti, D.; Zappia, G.; Delle Monache, G. Liebigs Ann. Chem. 1994, 641.
26. Blaskovich, M.A.; Lajoie, G.A. J. Am. Chem. Soc. 1993, 115, 5021.
27. (e) Kunieda, T.; Ishizuka, T.; Higuchi, T.; Hirobe, M. J. Org. Chem. 1988, 53, 3381.
28. (f) Takahata, T.; Yamazaki, T. J. Org. Chem. 1989, 54, 4812.
29. (a) Hanessian, S.; Vanasse, B. Can. J. Chem. 1993, 71, 1401.
30. (b) Gefflaut, T.; Bauer, U.; Airola, K.; Koskinen, A.M.P. Tetrahedron:Asymmetry 1996, 7, 3099.
31. Echalier, F.; Constant, O.; Bolte, J. J. Org. Chem. 1993, 58, 2747.
32. (a) Virtanen, A.I.; Ettala, T. Suomen Kemistilehti. 1956, B29, 107.
33. (b) Virtanen, A.I.; Ettala, T. Acta Chem. Scand. 1957, 11, 182.
34. Muller, A.L.; Uusheimo, K. Acta Chem. Scand. 1965, 19, 1987.
35. Synthesis and reactivity of 2,3-aziridino-γ-lactones : (a) Dubois, L.; Dodd, R.H. Tetrahedron 1993, 49, 901.
36. (b) Dubois, L.; Mehta, A.; Tourette, E.; Dodd, R.H. J. Org. Chem. 1994, 59, 434.
37. Dauban, P.; Dubois, L.; Tran Huu Dau, E.; Dodd, R.H. J. Org. Chem. 1995, 60, 2035.
38. Dauban, P.; Chiaroni, A.; Riche, C.; Dodd, R.H. J. Org. Chem. 1996, 61, 2488.
39. (e) Dauban, P.; Hofmann, B.; Dodd, R.H. Tetrahedron 1997, 53, 10743.
40. (f) Dauban, P.; Dodd, R.H. J. Org. Chem. 1997, 62, 4277.
41. Scriven, E.F.V.; Turnbull, K. Chem. Rev. 1988, 88, 298.
42. Corey, E.J.; Nicolaou, K.C.; Balanson, R.D.; Machida, Y. Synthesis 1975, 590.
43. Bayley, H.; Standring, D.N.; Knowles, J.R. Tetrahedron Lett. 1978, 3633.
44. The use of catalytic 1,3-propanedithiol in the presence of sodium borohydride has been reported to efficiently reduce azide groups. However, chemoselectivities of this methodology were not reported and consequently no attempt was made to apply this technique to compound 16. See : Pei, Y.; Wickham, B.O.S. Tetrahedron Lett. 1993, 34, 7509.
45. Knouzi, N.; Vaultier, M.; Carrié, R. Bull. Soc. Chim. Fr. 1985, 815.
46. For a review, see : Ley, S.V.; Norman, J.; Griffith, W.P.; Marsden, S.P. Synthesis 1994, 639.
47. Helaine, V.; Bolte, J. Tetrahedron:Asymmetry 1998, 9, 3855.
48. 13C NMR of compound 3 showed the presence of a mixture of diastereomers which would result from partial or complete epimerisation of one or more of the three chiral centers. Within the limits of detection of impurities by NMR, compound (3S,4S)-3 can thus be considered to be >95% pure.
49. A preliminary study of the pharmacological activity of (3S,4S)-3 with respect to glutamate receptors will be reported elsewhere.